Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
1
Jul |
Enigma Diagnostics Announces Successful Evaluation Of The Enigma FL By The UK’s Veterinary Laboratories AgencyCategory: Veterinary | Leave a Comment |
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory). BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK.
|
23
Mar |
QuickTox(TM) Kit For Melamine Detection In Raw Materials Used In Animal Feed And Pet Food ProductsCategory: Veterinary | Leave a Comment |
EnviroLogix Inc. has introduced the first five-minute, on-site immunoassay to detect melamine contamination in raw materials used in animal feed and pet food products. QuickTox Kit for Melamine was developed with speed, simplicity and sensitivity in mind. As sensitive as ELISA, it is designed to detect melamine contamination at 2.5 ppm, the threshold established by regulatory agencies worldwide for non-infant food products.
|
4
Dec |
Prionics Launches A Highly Effective Test For The Early Detection Of Bluetongue Virus (BTV)Category: Veterinary | Leave a Comment |
Prionics, a world leader in farm animal diagnostics, has launched a highly effective and reliable ELISA for the early detection of antibodies specific to the Bluetongue Virus (BTV) in cattle, sheep and goats. BTV causes disease outbreaks which can spread quickly among animal herds causing substantial economic losses in affected countries.
|
18
Nov |
PharmaCom BioVet, Inc. Collaborates With PetScreen, LTD, Leading Innovator Of Canine Cancer Early DetectionCategory: Veterinary | Leave a Comment |
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce a formal collaborative agreement with PetScreen, LTD, BioCity Nottingham, UK, to help improve cancer diagnosis and treatment for canines. PetScreen is the leading innovator of early detection of canine cancer. With one in three dogs developing cancer, early detection increases the chance of successful treatment and survival. Dr.
|
11
Sep |
Healionics Multi-Million Dollar STAR™ Biomaterial Supply Agreement With TR BioSurgical For Veterinary Glaucoma ImplantCategory: Veterinary | Leave a Comment |
Healionics Corporation, a provider of next generation biomaterial solutions to healthcare manufacturers, today announced that it has entered into a multi-million dollar manufacturing, supply and distribution agreement with TR BioSurgical, LLC (TRBIO) for use of its flagship STAR™ biomaterial scaffold in a veterinary glaucoma implant.